Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Correspondence

Perioperative management of patients with hip fractures and COVID-19: A single institution’s early experiences

Dear editor,

The COVID-19 pandemic caused the cancellation of all elective surgeries in New York State; nevertheless, non-elective surgeries still needed to be performed. The mortality and morbidity associated with a hip fracture is reduced if repair occurs within 48 h of admission [1]. Two international case series demonstrated elevated risk for perioperative morbidity and mortality following hip fracture repair in coronavirus patients [2,3]. On the contrary, we describe the successful management of five COVID-19 patients who underwent surgery.

After institutional review board (#2020-11706) approval at Montefiore Medical Center, a retrospective case series of patients undergoing surgical repair of a hip fracture between March 19, 2020 and April 30, 2020 was performed. Written consent to publish the case was obtained from patients.

Four patients presented with intertrochanteric (IT) fractures and one patient had a femoral neck fracture. Demographic information and a description of the surgical management are detailed in Table 1. All five patients presented with mild to moderate COVID-19 symptoms with some elevation of inflammatory markers (Ferritin in patients #2 and #3 and C-reactive protein in patients #2, #3, and #5). Hypercoagulability was demonstrated by an elevated D-dimer on the day of surgery in four patients. Prior to admission patient #5 was on Clopidogrel for peripheral vascular disease which was converted to therapeutic Enoxaparin on hospital admission and then continued postoperatively. The remaining three patients were started on Enoxaparin daily preoperatively and continued postoperatively. Low molecular weight heparin is preferred. In situations where heparin is contraindicated, non-heparin anticoagulation agents should be used.

Regional anesthesia has been shown to be safe in COVID-19 patients [5]. Spinal anesthesia was utilized in order to decrease the risk of viral aerosolization. Short cephalomedullary nail was used in three of the four patients with IT fracture to decrease surgery time and blood loss; subtrochanteric extension prevented its use in the fourth patient. The femoral neck fracture patient underwent uncemented hemiarthroplasty to reduce the risk of cardiopulmonary complications. General anesthesia was used due to heparin drip. Furthermore, early mobilization and rehabilitation of the post-surgical COVID-19 patient is recommended to improve functional status.

Tranexamic acid (TXA) is commonly used to limit blood loss for elective hip surgeries. Its efficacy and safety have been demonstrated in many studies on patients with minimal comorbidities, but there is limited data on patients at high-risk for thromboembolic events with COVID-19 infection. Thus, the routine use of TXA for this population is not recommended. Postoperative delirium is associated with poor surgical outcomes, underscoring the importance of multimodal analgesia for pain. The clinical presentation of patients with COVID-19 can vary from asymptomatic to critically ill. The severity of infection correlates with the elevation of biological markers. Based on our experiences, surgical repair should be reserved for patients with either mild or moderate symptoms.

Hip fractures typically occur in the elderly population and are complicated by multiple comorbidities. Active COVID-19 infection places these patients at increased risk for morbidity and mortality. Timely repair is preferable; however, in this case series we have shown that delayed surgical repair can also result in good surgical outcomes. Further research is needed to better establish surgical guidelines in the care of COVID-19 patients presenting with hip fractures, including how the surgical plan should be altered based on the severity of infection.

Contributions

Iyabo O. Muse, M.D.: The corresponding author. This author contributed to writing significant portions of the manuscript and revising the manuscript.

Eliliary Montilla, M.D.: This author wrote the anesthesia portion and review of the manuscript.

Konrad Gruson, M.D.: This author wrote the surgical portion of the manuscript.

Jay Berger, M.D., Ph.D.: This author wrote the disease effect on organ dysfunction section and revising significant portions in the paper.

Funding

Support was provided solely from institutional and/or departmental sources.
| Clinical characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|--------------------------|-----------|-----------|-----------|-----------|-----------|
| Age (years), sex         | 76, F     | 67, M     | 80, F     | 89, F     | 83, F     |
| BMI (kg/m²)              | 32        | 28        | 22        | 24        | 24        |
| Orthopedic diagnosis     | Femoral neck fracture | Intertrochanteric fracture | Intertrochanteric fracture | Intertrochanteric fracture w/ subtrochanteric extension |
| Type of surgery          | Uncemented hip HA | Short IMN | Short IMN | Short IMN | Long IMN |
| Type of anesthesia       | General anesthesia | Spinal | Spinal | Spinal | Spinal |

Comorbidities

| Diabetes | Yes | Yes | No | Yes | No |
| HTN      | Yes | Yes | Yes | Yes | Yes |
| Obesity (> 30 BMI) | Yes | No | No | Yes | No |
| Low ejection fraction (< 50%) | No | No | No | Yes | No |
| Heart disease (CAD, Pacemaker, dysrhythmia) | Yes | No | No | Yes | No |
| Dementia | Yes | No | No | No | Yes |
| Renal disease | Yes | No | Yes, on HD | Yes | No |
| Anemia | Yes | Yes | Yes | Yes | Yes |
| COPD | No | Yes | No | Yes | No |
| Asthma | Yes | No | No | Yes | No |
| Anticoagulation | Yes - Apixaban & Heparin drip | No | No | No | Yes - Clopidogrel |
| Smoking | No | Yes | No | Yes | No |
| Psychiatric issues | No | Yes | No | Yes | Yes |
| Peripheral vascular disease | Yes | No | No | Yes | Yes |
| Stroke | No | No | No | Yes | Yes |

Signs and Symptoms

| Fever | Yes | No | No | No | No |
| Cough | No | No | No | No | No |
| Low oxygenation (< 95%) | Yes | Yes | Yes | No | No |
| Dyspnea | No | No | No | Yes | Yes |

Laboratory test results

| White blood cell count (x10⁹/L) | 10.8 | 9.4 | 14.1 (↑) | 8.5 | 8.2 |
| Red blood cell count (x10⁹/L) | 3.13 (↓) | 3.58 (↓) | 2.85 (↓) | 3.41 (↓) | 4.48 |
| Neutrophil count (x10⁹/L) | 6.3 | 7.2 | 11.4 (↑) | 8.1 | 5.6 |
| Hemoglobin (x10⁹/L) | 9.0 (↓) | 10.0 (↓) | 8.2 (↓) | 9.3 (↓) | 8.6 (↓) |
| Platelet count (x10⁹/L) | 380 | 187 | 111 (↓) | 354 | 228 |
| PT (s) | 16.4 (↑) | 14.9 (↑) | 14.3 | 14 | 15.5 (↑) |
| PTT (s) | 32.7 | 37 | 39.7 | 29.6 | 33.9 |
| INR (ratio) | 1.3 | 1.1 | 1.1 | 1.1 | 1.2 |
| D-dimer (µg/mL) | N/A | 7.76 (↑) | 5.92 (↑) | 9.42 (↑) | 4.46 (↑) |
| Lactic dehydrogenase (U/L) | 253 (↑) | 242 (↑) | 396 (↑) | 247 (↑) | 273 (↑) |
| BUN (mmol/L) | 25 (↑) | 23 (↑) | 38 (↑) | 49 (↑) | 12 |
| Creatinine (µmol/L) | 1.02 | 1.05 | 5.85 (↑) | 1.2 | 0.45 |
| C-reactive protein (mg/dL) | 8.8 (↑) | 3.5 (↑) | 0.1 | 10.4 (↑) |
| Procalcitonin (ng/mL) | N/A | 0.2 (↑) | 0.9 (↑) | 0.1 | 0.2 (↑) |
| Ferritin (ng/ml) | 159 | 1725 (↑) | 508 (↑) | 146 | 173 |

Evidence of COVID-19

| SARS-COV-2 quantitative RT-PCR | Positive | Positive | Positive | Positive | Positive |
| Chest x-ray | Bilateral opacities | Bilateral opacities | Bilateral opacities/lung mets | No opacities | No opacities |

Treatments

| Oxygen therapy (NC, BIPAP) | Yes | Yes | No | No | Yes |
| Antibiotics | Yes | No | No | No | No |
| Anticoagulation | Yes - Apixaban | Yes - LMWH | Yes - LMWH & Apixaban | Yes - LMWH | Yes - LMWH |
| Hydrochloroquine | Yes | No | No | No | No |
| Antiviral therapy | No | No | No | No | No |
| Glucocorticoid therapy | No | No | No | No | No |
| Dialysis | No | No | Yes | No | No |
| Mechanical ventilation | No | No | No | No | No |
| Complications post-surgery | No | No | No | No | No |
| Co-bacterial pneumonia/ infection | No | No | No | No | No |
| Thrombotic event | No | No | No | No | No |
| Need for PRBC transfusion | Yes | Yes | Yes | Yes | Yes |
| Death | No | No | No | No | No |

(continued on next page)
Table 1 (continued)

| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|-----------|-----------|-----------|-----------|-----------|
| Time of surgery post admission (hours) | 48 | 24 | > 72 | 24 | > 72 |
| Length of hospitalization (days) | 15 | 9 | 11 | 8 | 11 |
| Discharged from hospital (days) | Yes - SAR | Yes - SAR | Yes - SAR | Yes - SAR | Yes - NH |

HA = hemiarthroplasty, IMN = intramedullary nail, BMI = body mass index, HTN = hypertension, COPD = chronic obstructive pulmonary disease, CAD = coronary artery disease, HD = hemodialysis, BUN = blood urea nitrogen, N/A = not available, Ferritin: normal range 25-270 ng/ml, SARS-COV-2 = severe acute respiratory syndrome coronavirus 2, RT-PCR = reverse transcription polymerase chain reaction, NC = nasal cannula, BIPAP = bilevel positive airway pressure, PRBC = packed red blood cells, PT = prothrombin time, PTT = partial thromboplastin time, INR = international normalized ratio, LMWH = low molecular weight heparin, SAR = subacute rehab, NH = nursing home.

* Hemoglobin: normal range 12.2-15.3g/dl.

† D-dimer: normal range 0.0-0.5μg/ml.

Declaration of competing interest

The authors declare no competing interests.

Acknowledgement

The authors thank Singh Nair, M.D., a researcher at the Department of Anesthesiology, Montefiore Medical Center for his guidance and Institutional Review Board support.

References

[1] Roberts KC, Brox WT. AAOS clinical practice guideline: management of hip fractures in the elderly. J Am Acad Orthop Surg 2015;23:138–40. https://doi.org/10.5435/JAAOS-D-14-00433.

[2] Catellani F, Coscione A, D’Ambrosi R, Usai L, Ruscitano C, Fiorentino G. Treatment of proximal femoral fragility fractures in patients with COVID-19 during the SARS-CoV-2 outbreak in northern Italy. J Bone Joint Surg Am 2020. https://doi.org/10.2106/JBJS.20.00617.

[3] Mi B, Chen L, Xiong Y, Xue H, Zhou W, Liu G. Characteristics and early prognosis of COVID-19 infection in fracture patients. J Bone Joint Surg Am 2020;102(9):750–8. https://doi.org/10.2106/JBJS.20.00390.

[4] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094–9. https://doi.org/10.1111/jth.14817.

[5] Zhong Q, Liu YY, Luo Q, et al. Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study. Br J Anaesth 2020;124(6):670–5. https://doi.org/10.1016/j.bja.2020.03.007.

Iyabo O. Muse (M.D., Assistant Professor)⁎, Eililary Montilla (M.D., Assistant Professor)b, Konrad I. Gruson (M.D., Associate Professor)c, Jay Berger (M.D., Ph.D., Assistant Professor)d

⁎ Department of Anesthesiology, Division of Regional Anesthesia and Pain Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States of America

b Department of Anesthesiology, Division of Regional Anesthesia and Pain Medicine, Montefiore Medical Center, New York, United States of America

c Department of Orthopedic Surgery, Division of Shoulder Surgery, Montefiore Medical Center, New York, United States of America

d Department of Anesthesiology, Department of Medicine, Division of Critical Care Medicine, Montefiore Medical Center, New York, United States of America

E-mail address: imuse@montefiore.org (I.O. Muse).